UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000004731 |
|---|---|
| Receipt number | R000005632 |
| Scientific Title | Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation. |
| Date of disclosure of the study information | 2010/12/15 |
| Last modified on | 2018/12/21 10:21:21 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2010/12/15 17:20:53 | ||
| 2 | Update | 2012/08/26 18:47:06 | Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
| 3 | Update | 2012/12/17 18:42:54 | Key exclusion criteria Key exclusion criteria |
|
| 4 | Update | 2014/06/17 16:23:10 | TEL Address Address |
|
| 5 | Update | 2015/06/15 15:25:04 | Recruitment status |
|
| 6 | Update | 2016/06/15 14:32:57 | Name of primary person or sponsor Organization |
|
| 7 | Update | 2018/12/21 10:21:21 | Recruitment status Anticipated trial start date Publication of results |
